Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2025)

Evommune (EVMN) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $326000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 9.44% to $326000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $686000.0, a N/A change, with the full-year FY2025 number at $1.4 million, up 7.93% from a year prior.
  • Depreciation & Amortization (CF) was $326000.0 for Q4 2025 at Evommune, down from $360000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $360000.0 in Q4 2024 to a low of $326000.0 in Q4 2025.